During the last session, Aclaris Therapeutics Inc (NASDAQ:ACRS)’s traded shares were 5.81 million, with the beta value of the company hitting 0.36. At the end of the trading day, the stock’s price was $3.96, reflecting an intraday loss of -13.73% or -$0.63. The 52-week high for the ACRS share is $5.17, that puts it down -30.56 from that peak though still a striking 80.56% gain since the share price plummeted to a 52-week low of $0.77. The company’s market capitalization is $282.87M, and the average intraday trading volume over the past 10 days was 9.53 million shares, and the average trade volume was 1.89 million shares over the past three months.
Aclaris Therapeutics Inc (ACRS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.57. ACRS has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Aclaris Therapeutics Inc (ACRS) registered a -13.73% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -13.73% in intraday trading to $3.96, hitting a weekly high. The stock’s 5-day price performance is 62.30%, and it has moved by 211.81% in 30 days. Based on these gigs, the overall price performance for the year is 321.19%. The short interest in Aclaris Therapeutics Inc (NASDAQ:ACRS) is 2.41 million shares and it means that shorts have 3.56 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.5, which implies an increase of 47.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $25 respectively. As a result, ACRS is trading at a discount of -531.31% off the target high and 24.24% off the low.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Statistics show that Aclaris Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Aclaris Therapeutics Inc (ACRS) shares have gone up 244.35% during the last six months, with a year-to-date growth rate more than the industry average at 58.06% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 20.67%. While earnings are projected to return 41.73% in 2024.
ACRS Dividends
Aclaris Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Aclaris Therapeutics Inc insiders own 2.66% of total outstanding shares while institutional holders control 73.55%, with the float percentage being 75.56%. BML CAPITAL MANAGEMENT, LLC is the largest shareholder of the company, while 108.0 institutions own stock in it. As of 2024-06-30, the company held over 12.99 million shares (or 18.2739% of all shares), a total value of $14.29 million in shares.
The next largest institutional holding, with 4.69 million shares, is of VANGUARD GROUP INC’s that is approximately 6.5952% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.16 million.
